43 results
6-K
EX-1.1
ENLV
Enlivex Therapeutics Ltd
29 May 24
Enlivex Therapeutics Closes up to $15 Million Registered Direct Offering
4:20pm
by insurers of recognized financial responsibility against such losses and risks and in such amounts as are prudent and customary for companies of similar
424B5
ENLV
Enlivex Therapeutics Ltd
29 May 24
Prospectus supplement for primary offering
4:15pm
contained or incorporated by reference in this prospectus supplement or in the accompanying prospectus. We take no responsibility for, and can provide … for more than one issue of warrants. A warrant agent will have no duty or responsibility in case of any default by us under the applicable warrant
6-K
EX-99.1
ENLV
Enlivex Therapeutics Ltd
29 Mar 24
Report of Foreign Private Issuer
4:30pm
included in the accompanying Management’s Annual Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion
6-K
EX-99.1
yq22m2 nvzx
31 Mar 23
Report of Foreign Private Issuer
4:30pm
6-K
EX-10.1
j2hvgdd9
30 Dec 22
Report of Foreign Private Issuer
4:02pm
424B5
c913a
30 Dec 22
Prospectus supplement for primary offering
4:01pm
F-3
4syu4sq1d2syofet
29 Apr 22
Shelf registration (foreign)
8:14am
6-K
EX-1.1
l5ynyyc87s3k9a3
12 Feb 21
Enlivex Announces Closing of Previously Announced Bought Deal Offering of Approximately $46.0 Million Ordinary Shares
5:17pm
424B5
eigopdt4 noxfc
10 Feb 21
Prospectus supplement for primary offering
5:22pm
424B5
wjw1grg
9 Feb 21
Prospectus supplement for primary offering
4:56pm
6-K
EX-10.1
rpr 3iga1a
22 Oct 20
Report of Foreign Private Issuer
8:47am
424B5
vnwu1rsg22yyr d45l
22 Oct 20
Prospectus supplement for primary offering
8:45am
6-K
EX-99.1
0d9i acp1rbo9468k
19 May 20
Annual and Extraordinary General Meeting of Shareholders
8:04am